14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー ［臨床試験数：145，薬物数：139（DrugBank：23），標的遺伝子数：12，標的パスウェイ数：21］
Searched query = "Chronic inflammatory demyelinating polyneuropathy", "Chronic inflammatory demyelinating poly (radiculo) neuropathy", "Multifocal motor neuropathy", "CIDP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||NCT02885259||September 2016||25/1/2016||HyQvia in Multifocal Motor Neuropathy||Subcutaneous Immunoglobulin With rHuPH20 in Multifocal Motor Neuropathy||Multifocal Motor Neuropathy||Drug: rHuPH20||UMC Utrecht||NULL||Not yet recruiting||18 Years||99 Years||Both||20||N/A||Netherlands|
|2||EUCTR2015-000828-28-NL||26/07/2016||30/11/2015||Immunoglobulins given under the skin to treat patients with multifocal motor neuropathy (MMN). To increase the amount of immunoglobulins, an enzyme is added that will temporarily create more space under the skin. This space is filled with immunoglobulins. By this way less infusions should be needed.||Titlle: Subcutaneous immunoglobulins with rHuPH20 in multifocal motor neuropathy (MMN) It is an interventional cross-over study where the use of the combination of subcutaneous immunoglobulins together with the enzyme hyaluronidase (rHuPH20) is compared with the current gold standard intravenous immunoglobulins (IVIg). Non-inferiority and tolerability are studied in 20 MMN patients. The reason to add rHuPH20 is to increase volumes per infusion and in this way contribute to reduced frequency of infusions. - Hymne||Non-inferiority and safety/tolerance of Hyqvia compared to IVIg in 20 MMN patients with at least one conduction block on EMG and stable on IVIg.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]||Trade Name: Hyqvia|
Product Name: Hyqvia
|UMC Utrecht||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|